Fibromyalgia's First Prescription: Choosing Among Three Drugs With No Head-to-Head Answer
A newly diagnosed patient needs a first fibromyalgia medication, and the honest answer is that the three FDA-approved options have never been tested directly against each other — the real decision has to be made on her own specific symptom picture instead.
J.M., a 34-year-old woman, was diagnosed with fibromyalgia six weeks ago after nearly two years of widespread pain, unrefreshing sleep, and a fatigue she initially attributed to being a new mother of two, before a rheumatologist's workup ruled out inflammatory causes and confirmed the diagnosis on exam and history. She also carries an existing diagnosis of generalized anxiety disorder, managed for the past three years with as-needed lorazepam that she uses roughly twice a week, more since the fibromyalgia symptoms began. She works part-time as a physical therapist assistant, a job whose physical demands she says has become noticeably harder over the past year, and when asked directly what bothers her most day to day, she named her sleep first — waking multiple times a night regardless of how tired she is — then her anxiety, then the fatigue itself, almost as an afterthought.
Three drugs carry FDA approval specifically for fibromyalgia — pregabalin, duloxetine, and milnacipran — and no published randomized trial has ever compared them directly against one another; each was tested against placebo in its own separate trial program, leaving genuine, unresolved uncertainty about which one actually works best, for whom, a gap the field has simply never closed with a real head-to-head study. What the separate trial literatures do offer is a secondary-symptom profile for each drug distinct enough to matter: pregabalin's sedating effect gives it a real, if modest, sleep benefit beyond pain relief; duloxetine carries a second FDA approval for generalized anxiety disorder specifically, meaning it could plausibly treat two of her three named priorities with one prescription; milnacipran's profile leans more activating, better matched to fatigue-predominant presentations than to hers. Read against what she herself named as mattering most — sleep, then anxiety, then fatigue — the choice starts to look less like picking the objectively superior drug, since no trial has ever crowned one, and more like matching a real option to her actual priorities.
First-visit treatment planning
Pregabalin has the largest individual trial base of the three FDA-approved agents, and its sedating profile gives it a real secondary benefit for her sleep disruption — the symptom she herself named first. I'd start there.
I'd weigh her GAD more heavily than that leaves room for. Duloxetine carries FDA approval for both fibromyalgia and generalized anxiety disorder specifically — one prescription that could genuinely treat two of her diagnoses rather than layering a second medication onto a fibromyalgia- only choice. She's already using lorazepam more often since her fibromyalgia symptoms started; that's a real sign her anxiety isn't a background footnote right now.
Sleep matters, but treating it in isolation from an anxiety disorder that's visibly worsening risks under-addressing the thing most likely driving some of that sleep disruption in the first place.
Neither of you is wrong about your drug — you're each reading a real secondary benefit correctly. But there's no head-to-head trial anywhere in the literature comparing pregabalin, duloxetine, and milnacipran against each other; each was only ever tested against placebo separately. That means this isn't resolvable by arguing which drug is "better" in the abstract. She told us directly what she prioritizes — sleep first, anxiety second, fatigue third. That ranking, not a trial that doesn't exist, is what should settle it.
Both of your arguments are actually consistent with her own ranking, not opposed to it — sleep first does point toward pregabalin, but her anxiety concern is real enough to weigh second, which argues for treating pregabalin as the starting choice and revisiting duloxetine explicitly if anxiety doesn't improve on its own once sleep and pain settle.
Agreed: start pregabalin, titrated with attention to her sleep response specifically; leave lorazepam unchanged for now; and set an explicit 6-week follow-up with duloxetine named directly as the next step if her anxiety symptoms haven't improved once pain and sleep are addressed. The pharmacologist's reframing — that her own stated priority ranking, not a nonexistent head-to-head trial, should decide this — was what both other voices signed onto, including the pain medicine specialist's own final read that this doesn't actually conflict with weighing her anxiety seriously, just sequences it.
Not addressed today: whether her lorazepam use, already having crept upward, warrants its own separate conversation about benzodiazepine reliance independent of which fibromyalgia drug she starts. Flagged for the follow-up visit rather than folded into today's decision.